CJC-1295 With DAC vs Without DAC

CJC-1295 with DAC and CJC-1295 without DAC share a name, but they are not two strengths of the same product. The distinguishing feature is a single chemical addition, a linker technology called drug affinity complex (DAC), that lets one version bind to a protein in blood plasma and stay in circulation for days while the other clears far faster^[1]. That is also the practical answer to a question that keeps coming up in research-peptide forums, including a recent r/peptides post asking which version is better suited for a given use^[9]. Neither one is "better" without specifying which molecule is meant. They are different compounds with different pharmacokinetics, and a comparison that skips that step doesn't tell you anything useful.

Two molecules, not one product line

Analytical chemists treat them as separate compounds, not variants of a single item. Memdouh and colleagues, writing in Drug Testing and Analysis in 2021, built anti-doping detection methods for four growth-hormone-releasing hormone (GHRH) analogues and listed "CJC-1295" and "CJC-1295 with drug affinity complex" as two of the four distinct entries they studied^[3]. PubChem's own records confirm the two are chemically different. The without-DAC molecule, also called MOD-GRF(1-29) in the literature, is a 29-residue peptide with the molecular formula C152H252N44O42^[4]. The with-DAC molecule is larger, C165H269N47O46, because it carries the extra linker ConjuChem's DAC technology adds to the same GHRH-derived backbone^[5]. A vendor page that uses "CJC-1295" to mean whichever version it happens to be selling is glossing over that difference.

The published human data is almost entirely about the with-DAC version

Teichman and colleagues ran two placebo-controlled, ascending-dose studies in healthy adults aged 21 to 61 and reported a plasma half-life of 5.8 to 8.1 days for CJC-1295 with DAC, mean growth-hormone concentrations 2 to 10 times baseline for 6 days or more after a single dose, and IGF-1 elevated for 9 to 11 days^[1]. A companion study by Ionescu and Frohman, in a similar healthy-adult population, found that despite that multi-day presence in the blood, the pituitary gland's normal pulsatile pattern of growth-hormone release was preserved rather than flattened, with basal GH roughly 7.5 times baseline and mean GH and IGF-1 up 46% and 45%^[2]. Both studies describe the with-DAC compound as generally well tolerated over that short observation window in healthy volunteers. We could not find a published human pharmacokinetic study of the without-DAC version on its own. Structurally, it is the short GHRH(1-29) fragment without the albumin-binding linker, so there is no chemical reason to expect it shares the days-long profile Teichman measured, but that is an inference from the molecule's structure, not a separately measured result.

What we don't yet know

Neither version has a completed later-stage human efficacy trial behind it. The with-DAC compound has two small, short early-phase pharmacokinetic studies in healthy adults; the without-DAC compound has no dedicated human pharmacokinetic study we could locate at all. Nothing in the record covers months or years of use, pregnancy, older adults, or people with existing metabolic conditions. And because nothing requires a vendor to identity-test what actually goes into a vial sold as "CJC-1295," a reader comparing notes with someone else online has no guarantee either of them is describing the same molecule.

Neither version is an approved medicine

Regulatory status does not separate the two versions, because neither is authorised anywhere in our coverage area. A search of the European Medicines Agency's public medicines database returns no marketing authorisation or European public assessment report for CJC-1295 in any form^[6]. In the United States, DailyMed's only listing for CJC-1295 is a bulk ingredient product for animal drug compounding, not a human medicine^[7]. That puts it in different regulatory territory from tesamorelin, a related GHRH analogue that does have an FDA-approved human product on DailyMed, marketed as Egrifta^[8]. CJC-1295, with or without DAC, has no equivalent in any jurisdiction we track.

What this means if you're trying to compare them

If you're reading product listings or forum threads that treat "CJC-1295" as one thing, the DAC distinction is the first fact to check, because it changes the entire pharmacokinetic picture the published research describes. Checking it doesn't fix the bigger problem. Even the better-studied with-DAC version rests on two small early-phase studies, and no later trial has confirmed them. A forum thread, including the one that prompted this article^[9], can tell you what people report experiencing. It cannot tell you which molecule they actually used, at what dose, or from what source. Our full CJC-1295 reference page carries the complete source list and the country-by-country regulatory picture.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed here may be classified as prescription medicines or research chemicals depending on your jurisdiction. If you are considering a GHRH-axis peptide for any reason, that is a conversation for a qualified healthcare professional who knows your medical history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.